Substrate
Topic

Prader-Willi syndrome

1 stories related to this topic, newest first.

Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9 BillionSubstrate placeholder — needs review
world31 days ago

Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences has entered an agreement to purchase Soleno Therapeutics for $2.9 billion in cash. The acquisition aims to broaden Neurocrine's portfolio in treatments for rare genetic disorders. Soleno's lead product, DCCR, targets Prader-Willi syndrome, a rare condition…

BU
1 source